Screening for Prediabetes and Type 2 Diabetes Mellitus – Putting Prevention into Practice


 

Putting Prevention into Practice

An Evidence-Based Approach

 

Am Fam Physician. 2022 Jan ;105(1):73-74.

Related USPSTF Clinical Summary: Screening for Prediabetes and Type 2 Diabetes

Author disclosure: No relevant financial affiliations.

Case Study

A 36-year-old, D.P., presents to your clinic as a new patient for a wellness visit. D.P. has no current health concerns but states that they had gestational diabetes during their last pregnancy three years ago. The patient reports that their father has diabetes mellitus and takes insulin. D.P.’s body mass index is 26 kg per m2, and pulse and blood pressure are normal.

Case Study Questions

1. According to the U.S. Preventive Services Task Force (USPSTF) recommendation statement, is screening for prediabetes and type 2 diabetes appropriate for this patient?

  • A. Yes, all adults with multiple risk factors should begin screening starting at 35 years of age.

  • B. Yes, all adults, regardless of risk factors, should begin screening starting at 35 years of age.

  • C. Yes, all patients who have overweight or obesity should be screened starting at 35 years of age.

  • D. No, because this patient has a body mass index less than 30 kg per m2, screening should start at 40 years of age.

  • E. No, only patients with symptoms of diabetes should be screened starting at 35 years of age.

2. D.P. completes screening and is found to have prediabetes. Based on the available evidence reviewed by the USPSTF, which of the following statements about interventions for prediabetes are correct?

  • A. Lifestyle interventions and taking metformin are associated with preventing progression of prediabetes to type 2 diabetes.

  • B. Taking metformin has a beneficial effect on cardiovascular disease risk factors, including blood pressure and lipid levels.

  • C. Lifestyle interventions and taking metformin have a beneficial effect on weight.

  • D. Lifestyle interventions have a beneficial effect on cardiovascular disease risk factors, including blood pressure and lipid levels.

3. According to the USPSTF recommendation statement, which one of the following statements about prediabetes and diabetes is correct?

To see the full article, log in or purchase access.

Author disclosure: No relevant financial affiliations.

References

1. Davidson KW,
Barry MJ,
Mangione CM,

et al.
Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement. JAMA.
2021;326(8):736–743.

2. Jonas DE,
Crotty K,
Yun JDY,

et al.
Screening for prediabetes and type 2 diabetes: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA.
2021;326(8):744–760.

3. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020: estimates of diabetes and its burden in the United States. Accessed November 15, 2021. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf

This PPIP quiz is based on the recommendations of the USPSTF. More information is available in the USPSTF Recommendation Statement and supporting documents on the USPSTF website (https://www.uspreventiveservicestaskforce.org). The practice recommendations in this activity are available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-for-prediabetes-and-type-2-diabetes.

This series is coordinated by Kenny Lin, MD, MPH, deputy editor.

A collection of Putting Prevention Into Practice published in AFP is available at https://www.aafp.org/afp/ppip.

 

Copyright © 2022 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact
afpserv@aafp.org for copyright questions and/or permission requests.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.